Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Debt (2016 - 2023)

Historic Total Debt for Amicus Therapeutics (FOLD) over the last 15 years, with Q2 2023 value amounting to $13.0 million.

  • Amicus Therapeutics' Total Debt fell 3249.77% to $13.0 million in Q2 2023 from the same period last year, while for Jun 2023 it was $13.0 million, marking a year-over-year decrease of 3249.77%. This contributed to the annual value of $21.4 million for FY2022, which is 1331.75% up from last year.
  • According to the latest figures from Q2 2023, Amicus Therapeutics' Total Debt is $13.0 million, which was down 3249.77% from $12.7 million recorded in Q1 2023.
  • In the past 5 years, Amicus Therapeutics' Total Debt ranged from a high of $147.8 million in Q2 2020 and a low of $8.9 million during Q4 2020
  • Its 5-year average for Total Debt is $63.1 million, with a median of $19.8 million in 2021.
  • Its Total Debt has fluctuated over the past 5 years, first skyrocketed by 160923.26% in 2019, then plummeted by 9396.09% in 2020.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Total Debt stood at $147.4 million in 2019, then plummeted by 93.96% to $8.9 million in 2020, then surged by 112.36% to $18.9 million in 2021, then rose by 13.32% to $21.4 million in 2022, then plummeted by 39.28% to $13.0 million in 2023.
  • Its Total Debt was $13.0 million in Q2 2023, compared to $12.7 million in Q1 2023 and $21.4 million in Q4 2022.